Fulcrum Gutted Its Pipeline. Then It Became Someone Else's Ride to Nasdaq.

The company also has a bispecific antibody in the works, SLTE-2100, which targets both PACAP/VIP and CGRP simultaneously. That one's still in early optimization, with clinical entry expected in late 2027.

SLTE-1009 is currently cleared for a Phase 1 trial in Australia, with initial safety data expected around mid-2027 and a Phase 2 migraine study planned for the second half of that year. In other words, Slate is early. Very early. But it has a credible scientific story and, more importantly, it just attracted some very serious money.

Follow the Money

The $245 million private placement tells you a lot about how the market views this deal. It was led by Frazier Life Sciences, with a roster of co-investors that reads like a who's-who of healthcare venture capital: Forbion, RA Capital Management, Deep Track Capital, Foresite Capital, OrbiMed, RTW Investments, and Mingxin Capital.

These aren't tourists. When that many top-tier healthcare funds pile into an oversubscribed round, it signals genuine conviction in the science. The financing alone would have been a strong headline. Pairing it with a public listing makes the whole package more attractive for investors who want eventual liquidity.

Here's how the ownership math shakes out after the deal closes. Slate's existing shareholders will control about 55.9% of the combined company. Private placement investors get roughly 39.1%. And Fulcrum's legacy holders are left with that slender 5% slice, which could adjust based on Fulcrum's net cash at closing (expected to be around $20.3 million).

Fulcrum shareholders won't walk away empty-handed, though. The company plans to pay an estimated $270 million cash dividend to pre-merger stockholders right before closing. For a stock that was trading around $3.79 before the announcement, that's a meaningful payout.

The Reverse Merger Playbook Is Back

Slate isn't the first private biotech to use a struggling public company as its on-ramp to Nasdaq, and it won't be the last. The strategy fell somewhat out of favor in 2025, when commentators noted that reverse mergers had "lost their luster." But 2026 has brought a resurgence.

Damora Therapeutics pulled off a reverse merger with a $285 million PIPE in 2025. Yarrow Bioscience did one with $200 million in concurrent financing. Serapha Bio and Boundless Bio combined in a $230 million deal. The pattern is consistent: private company with a promising pipeline, plus distressed public shell, plus a fat financing round, equals instant Nasdaq listing.

Why not just do a traditional IPO? Because IPOs have been brutal. Only 11 biotech companies went public on U.S. exchanges in 2025, according to IQVIA. When the front door is jammed, you find a side entrance. Reverse mergers are that side entrance, and they come with a built-in bonus: the deal structure lets the private company's investors retain near-total control of the equity.

What to Watch

The combined company will trade under the ticker SLTE once the deal closes, which is expected in Q4 2026. From there, the timeline is all about SLTE-1009. Phase 1 safety data in mid-2027 will be the first real test of whether Slate's PACAP/VIP approach works in humans.

For Fulcrum shareholders, the calculus is straightforward: cash out via the $270 million dividend, hold a small stake in a migraine company, or both. The investment thesis has changed completely, from sickle cell to headaches, from late-stage regulatory battle to early-stage clinical bet.

The bigger story, though, isn't about any single deal. It's about what happens when an entire sector's IPO window stays mostly shut. Capital doesn't stop flowing; it just finds creative plumbing. In 2026, that plumbing increasingly looks like a reverse merger with a company that used to do something else entirely.

Fulcrum spent years trying to fix sickle cell disease. Now its most valuable asset might be its stock ticker.

LEO Pharma Just Paid $435M for a Drug That Isn't Approved Yet

LEO Pharma is spending up to $435 million on a drug that isn't even approved yet. But dersimelagon could be the first real treatment for a brutal sun allergy, and LEO's rare-dermatology shopping spree is starting to look like a masterplan.